Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals

0:00-20:23

Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump’s Most Favored Nation drug pricing scheme.

Publisher

BioSpace

Published

September 2, 2026

Duration

20 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#bmspausedcar #revmedspancreaticcancer #mfndeals #lifesciences

The Nile